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Comparison of the results of electrophysiologic 
testing after short-term and long-term treatment 
with amiodarone in patients with ventricular 
tachycardia 
The results of electrophysiologic testing after short-term and long-term treatment with 
amiodarone were compared in 71 patients with ventricular tachycardia. Electrophysiologic testing 
was performed in the baseline state after 11 * 3 days of treatment with 1.2 to 2.4 gm/day of 
amiodarone, and after 13 + 4 weeks of therapy with a daily amiodarone dose of 400 mg. After 
short-term therapy, 62% of the patients had an adequate response to amiodarone. In 27 patients 
who were hemodynamically unstable, ventricular tachycardia was induced and became 
noninducible or hemodynamically stable after combination therapy with a class I agent. Among 
18 patients who did not have inducible ventricular tachycardia after short-term therapy, eight 
(44%) had inducible, hemodynamically unstable ventricular tachycardia after long-term treatment 
with amiodarone. On the other hand, six of the 27 patients who had hemodynamically unstable 
ventricular tachycardia after short-term therapy had an adequate response after long-term 
treatment with amiodarone. Therefore an adequate electrophysiologic response after short-term 
therapy does not guarantee a similar response after long-term treatment, and an inadequate 
response after short-term therapy does not always predict a similar response after long-term 
therapy. (AM HEART J 1991;121:1693.) 
Shimon Rosenheck, MD, Joao Sousa, MD, Hugh Calkins, MD, Stephan Schmaltz, 
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Because amiodarone has a prolonged half-life, sev- 
eral weeks of treatment may be necessary before its 
maximal electrophysiologic effects become mani- 
fest.l-” To hasten the onset of its therapeutic effect, 
amiodarone has often administered in high dosages 
for 1 to 2 weeks, after which time electrophysiologic 
testing has been performed.6-g However, although 
some previous studies have demonstrated that the 
results of electrophysiologic testing after 2 to 3 
months of treatment with a maintenance does of 
amiodarone are concordant with the results of test- 
ing after short-term treatment,6-8 other studies have 
not confirmed this,lO, l1 and it is unclear whether an 
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electrophysiologic test is clinically necessary after 
several weeks of therapy with amiodarone. Therefore 
the purpose of the present study was to compare the 
results of electrophysiologic testing after 2 weeks and 
after 2 months of treatment with amiodarone in a 
large group of patients who had ventricular tachy- 
cardia. 
METHODS 
Characteristics of patients. The subjects of the study 
were 71 consecutive patients who were treated with amio- 
darone for sustained ventricular tachycardia and who un- 
derwent electrophysiologic testing after 2 weeks and after 
2 to 3 months of treatment with amiodarone. There were 
63 men and eight women, with a mean age of 60 ? 11 years 
( f standard deviation). Sixty-six patients had coronary 
artery disease, two patients had valvular heart disease, and 
three patients had no evidence of structural heart disease. 
The mean left ventricular ejection fraction was 0.31 -t 0.13. 
Sixty-six patients had inducible sustained monomorphic 
ventricular tachycardia during baseline electrophysio- 
logic tests that were performed for evaluation of sustained 
ventricular tachycardia (47 patients), ventricular fibrilla- 
1693 
1694 Rosenheck et al. 
June 1991 
American Heart Journal 
tion (4 patients), unexplained syncope (7 patients), or 
nonsustained ventricular tachycardia (8 patients). Five 
patients did not have a baseline electrophysiologic study in 
the drug-free state because they were treated with amio- 
darone after they had had frequent recurrences of ventric- 
ular tachycardia that were resistant to other antiarrhyth- 
mic agents. Before treatment with amiodarone, the pa- 
tients underwent unsuccessful electropharmacologic 
testing with 1.4 -t 0.7 class I antiarrhythmic drugs; in ad- 
dition, a mean of 1.5 * 0.8 other class I antiarrhythmic 
agents failed to control ventricular tachycardia on a clin- 
ical basis. 
Amiodarone treatment. The 71 patients were treated 
orally for 11 -t 3 days with 1.2 to 2.4 gm/day amiodarone. 
The total mean loading dose of amiodarone was 17.3 ? 6.8 
gm. The mean plasma amiodarone concentration at the 
time of the first electrophysiologic test was 1.7 & 0.7 mg/ 
ml, and the mean desethylamiodarone concentration was 
0.9 ? 0.3 mg/ml. All 71 patients were retested after 13 t 4 
weeks of therapy with a daily amiodarone dose of 400 mg. 
After the first electrophysiologic test, 27 patients were 
treated with a class I antiarrhythmic agent in combination 
with amiodarone, and in these patients the class I drug was 
discontinued at least 5 half-lives before the second electro- 
physiologic test. The mean plasma amiodarone concentra- 
tion at the time of the second test was 1.4 * 0.5 mg/ml 
(p < 0.01, compared with the concentration at the time of 
the first test), and the mean desethyl-amiodarone concen- 
tration was 1.1 * 0.3 mg/ml (p < 0.001). 
Electrophysiologic study protocol. Electrophysiologic 
testing was performed in the fasting, unsedated state (af- 
ter informed consent was obtained) with the use of two or 
three quadripolar electrode catheters, which were posi- 
tioned in the right atrium, the right ventricular apex and 
outflow tract, and across the tricuspid valve to record the 
His bundle electrogram. A 5F catheter that was introduced 
into a femoral artery was used to monitor the arterial pres- 
sure. Leads Vi, I, III, and the intracardiac electrograms 
were recorded on a Siemens Elema Mingograf 7 recorder 
(Siemens Medical Systems Inc., Iselin, N.J.) at a paper 
speed of 25 to 100 mm/set. Two-millisecond pulses were 
delivered by a programmable stimulator (Bloom Associates 
Ltd.), Reading, Pa.). Programmed ventricular stimulation 
was performed with one to three extrastimuli and a basic 
drive train duration of 8 beats, a 3- or 4-second intertrain 
pause, and three basic drive train cycle lengths (350, 400, 
500, or 600 msec or sinus rhythm). Programmed stimula- 
tion was performed first et the right ventricular apex and 
then at the outflow tract or septum. 
Ventricular effective refractory periods were measured 
by scanning diastole with an extrastimulus in decrements 
of 10 msec. The longest coupling interval that did not re- 
sult in a ventricular response was considered to be the ven- 
tricular effective refractory period. The end point for pro- 
grammed stimulation was the induction of hemodynami- 
tally unstable monomorphic ventricular tachycardia or the 
completion of the entire protocol. Polymorphic ventricular 
tachycardia and ventricular fibrillation were not consid- 
ered end points for testing. 
Nonsustained ventricular tachycardia was defined as 
ventricular tachycardia that was six beats to 30 seconds in 
duration. Sustained ventricular tachycardia was defined as 
ventricular tachycardia that was greater than 30 seconds in 
duration or that required direct-current countershock or 
pacing to terminate. Hemodynamically stable ventricular 
tachycardia was defined as ventricular tachycardia that 
was associated with a mean arterial pressure greater than 
65 mm Hg with the patient in the supine position.‘* 
The criteria that were used to define an adequate 
response to amiodarone during electrophysiologic testing 
consisted of the complete suppression of inducible ventric- 
ular tachycardia, the induction of only nonsustained ven- 
tricular tachycardia that was less than 15 beats in duration, 
or the induction of sustained ventricular tachycardia that 
was hemodynamically stable. These criteria were used be- 
cause previous studies have demonstrated that they are 
associated with a low risk of arrhythmia-related death in 
patients who are treated with amiodarone.‘” 
Statistical analysis. A mixed model analysis of variance 
was used to compare the results of electrophysiologic test- 
ing in the baseline state and after short-term and long-term 
therapy with amiodarone. The amiodarone and desethyla- 
miodarone plasma concentrations after short-term and 
long-term treatment were compared with the use of a 
paired t test. The results of the electrophysiologic testing 
after short-term and long-term therapy were compared 
with Pearson’s chi-square test with the Bonferroni’s cor- 
rection for multiple comparisons and Fisher’s least signif- 
icant differences multiple comparisions. A p value of less 
than 0.05 was considered significant. 
RESULTS 
Electrophysiologic effects of amiodarone. The mean 
sinus cycle length, AH and HV intervals, QRS dura- 
tion, and QT interval increased significantly from 
baseline values after short-term therapy with amio- 
darone and remained unchanged after long-term 
therapy (Table I). At a basic drive cycle length of 600 
msec, the ventricular effective refractory period in- 
creased from the baseline value by a mean of 
17 % f 12 % (p < 0.0001) after short-term treatment 
with amiodarone and by 14% rt 11% (p < 0.0001) 
after long-term treatment. There was no significant 
change in the ventricular effective refractory period 
between the short-term and long-term tests. The re- 
sults were similar at a basic drive train cycle length 
of 400 msec (Table I). 
Baseline ventricular tachycardia characteristics. six- 
ty-six patients underwent baseline electrophysio- 
logic tests in the absence of antiarrhythmic drug 
therapy. The mean cycle length of ventricular tachy- 
cardia that was induced in the baseline test was 
285 k 56 msec, and the mean arterial pressure dur- 
ing the period of induced ventricular tachycardia was 
47 f 17 mm Hg. In 10 patients, the mean arterial 
pressure during ventricular tachycardia ranged be- 
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tween 65 to 80 mm Hg (mean 76 +- 8 mm Hg), and in 
these patients the mean ventricular tachycardia cy- 
cle length was 336 + 50 msec. In the other 56 
patients, the mean ventricular tachycardia cycle 
length was 274 -t 49 msec, and the mean arterial 
pressure ranged between 20 and 63 mm Hg (mean 
41 +- 12 mm Hg). 
Short-term effect of amiodarone on the induction of 
ventricular tachycardia. Among the 71 patients who 
underwent electrophysiologic tests after 11 + 3 days 
of amiodarone treatment, 44 had an adequate re- 
sponse to amiodarone; no ventricular tachycardia 
could be induced in 18 patients, only nonsustained 
ventricular tachycardia was induced in eight pa- 
tients, and hemodynamically stable ventricular ta- 
chycardia was induced in 18 patients. In the remain- 
ing 27 patients, hemodynamically unstable ventricu- 
lar tachycardia, which had a mean cycle length of 
346 rt 58 msec and which was associated with a mean 
arterial pressure of 50 f 8 mm Hg, was induced. In 
these patients, a class I antiarrhythmic agent was 
combined with amiodarone to obtain a satisfactory 
effect on the inducibility of ventricular tachycardia. 
Amiodarone was used with mexiletine in eight pa- 
tients, with quinidine in nine patients, with encain- 
ide in seven patients, with flecainide in two patients, 
and with tocainide in one patient. In one patient 
ventricular tachycardia was noninducible and in an- 
other only nonsustained ventricular tachycardia 
could be induced. In the remaining 25 patients, a 
slower and hemodynamically stable ventricular ta- 
chycardia was induced. The mean ventricular tachy- 
cardia cycle length in these 26 patients increased 
from 347 + 57 msec to 411 & 71 msec (p < O.Ol), and 
the mean arterial pressure increased from 50 ? 8 mm 
Hg to 75 a 14 mm Hg (p < 0.001) after addition of 
the class I antiarrhythmic agent. 
Long-term effect of amiodarone on induction of ven- 
tricular tachycardia. All patients underwent another 
electrophysiologic test, after 13 -+ 4 weeks of therapy 
with amiodarone, to evaluate the efficacy of long- 
term treatment with amiodarone in preventing the 
induction of hemodynamically unstable ventricular 
tachycardia. In 34 patients (45%), amiodarone was 
effective in suppressing the induction of hemody- 
namically unstable ventricular tachycardia, and in 39 
patients (55%) it was not. The mean cycle length of 
the induced ventricular tachycardia in these 39 
patients was 332 ?Z 56 msec, and the mean arterial 
pressure during the ventricular tachycardia was 
42 f 11 mm Hg. Ten of the 39 patients underwent 
implantation of an automatic cardioverter/defibril- 
lator; two other patients did not give consent for a 
defibrillator implantation and continued on combi- 
Table I. The effect of amiodarone on sinus cycle length; 
nodal, infranodal, and intraventricular conduction; and 






SCL (msec) 853 i 176 939 * 1?34* 955 i- 190* 
AH (msec) 108 f 35 122 i 41* 119 i 45* 
HV (msec) 53 * 14 61 + 17t 64 k 23t 
QRS (msec) 113 f 27 128 k 30* 129 + 31* 
QT (msec) 391 2 27 460 f 70* 456 -t 50” 
VERP at 600 254 k 20 293 +- 27* 291 + 23* 
msec 
VERP at 400 238 + 18 272 Z!I 26* 272 I 20* 
msec 
There were no significant differences between short-term and long-term 
therapy with amiodarone. 
Short-term amio, Electrophysiologic study after 11 + 3 days a high-dose 
amiodarone treatment; Long-term amio, electrophysiologic study after 
12 f 3 weeks of amiodarone treatment; XL, sinus cycle length; AH, AH 
Interval duration; HV, HV interval duration; VERP, ventricular effective 
refractory period. 
*p < 0.0001 compared with baseline. 
tp < 0.05 compared with baseline. 
nation therapy with quinidine or encainide. Twenty- 
seven patients had long-term therapy with a combi- 
nation of amiodarone and a class I antiarrhythmic 
agent. 
Comparison of the results of the testing after short- 
term and after long-term therapy. Among 44 patients 
who had favorable responses during electrophysio- 
logic testing after short-term therapy with amio- 
darone, 18 (41% ) no longer had favorable responses 
after long-term therapy and had inducible sustained, 
hemodynamically unstable ventricular tachycardia. 
On the other hand, among the 27 patients who had 
inadequate responses after short-term therapy, 6 
(22 % ) had favorable responses after long-term ther- 
apy and no longer had inducible hemodynamically 
unstable ventricular tachycardia. These results are 
summarized in Table II. 
Of the 18 patients who did not have inducible ven- 
tricular tachycardia after short-term therapy, ven- 
tricular tachycardia remained noninducible after 
long-term therapy in only six. Eight of the 18 patients 
(44 % ) had inducible ventricular tachycardia, which 
was hemodynamically unstable after long-term ther- 
apy. 
Overall, in 34% of the 71 patients in this study, the 
results of programmed ventricular stimulation after 
short-term therapy with amiodarone did not accu- 
rately predict the results after long-term therapy. 
None of these patients experienced hemodynami- 
tally unstable ventricular tachycardia or sudden 
death during the interval between the two tests. 
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Table II. Comparison of the response to programmed ven- 
tricular stimulation after short-term and long-term ther- 
apy with amiodarone in ‘71 patients 
Short-term therapy Long-term therapy* 
No VT 18 6 2 2 a 
Non-sust VT 8 3 1 0 4 
Stable VI 18 2 1 9 6 
Unstable VT 27 2 1 21 
TOTALS ?i 13 5 
2 
14 39 
(p < 0.0001). There was no significant difference in 
the tachycardia cycle length between short-term and 
long-term amiodarone therapy (Table III). 
The mean blood pressure during the tachycardia 
increased by 53 % +- 73 % between the baseline state 
and the early follow-up study 0, < O.OOOl), but by 
only 27 % f 73 % between the baseline state and the 
late follow-up study (p < 0.01). The decrease of 
11% * 37% between the early and the late studies 
was also significant (p < 0.001). There was a signifi- 
cant linear correlation between the ventricular ta- 
chycardia cycle length and the mean blood pressure 
in all three studies (p < 0.01). 
VT, Ventricular tachycardia. Non-sust, nonsustained.*p < 0.001 compared 
with short-term therapy. 
Table Ill. The effect of amiodarone on the cycle length of 
the induced sustained and nonsustained ventricular ta- 
chycardia and on the blood pressure during the tachycar- 
dia 
VTCL BP 
Condition Patients (msec) (mm Hd 
Baseline 63 285 k 56 47 zk 17 
Short-Term Amio 51 365 -1- 56* 66 t 20* 
Long-Term Amio 56 361 k 70* 56 zk 22t 
VTCL, Mean cycle length of the ventricular tachycardia; BP, blood pressure 
during the tachycardia; other abbreviations as in Table I. 
*p < 0.0001 compared with baseline. 
tp < 0.01 compared with baseline and p < 0.001 compared with Short-term 
amio. 
However, three patients had documented episodes of 
hemodynamically stable ventricular tachycardia dur- 
ing this interval. 
Among 45 patients with documented ventricular 
tachycardia, the clinical ventricular tachycardia was 
reproduced during the baseline electrophysiologic 
tests in 64%. After short-term therapy, ventricular 
tachycardia could be induced in 75 % of patients, and 
in 47% of them, the tachycardia had the same mor- 
phology as the ventricular tachycardia that was 
induced in the baseline state. After long-term ther- 
apy with amiodarone, ventricular tachycardia could 
be induced in 82 % of the patients, and in 60% of 
them the tachycardia had the same morphology as 
the ventricular tachycardia that was induced in the 
baseline state. 
Among the patients with inducible ventricular ta- 
chycardia after short-term therapy with amiodarone, 
the ventricular tachycardia cycle length increased by 
30% f 30% compared with the baseline state 
(p < O.OOOl), and among the patients with inducible 
ventricular tachycardia after long-term therapy with 
amiodarone, the tachycardia cycle length increased 
by 29% + 23 % compared with the baseline state 
DISCUSSION 
Main findings. This study demonstrates that the re- 
sults of electrophysiologic testing after short-term 
and long-term treatment with amiodarone are dis- 
cordant in 34% of patients who are treated for sus- 
tained ventricular tachycardia. In 22 % of patients in 
whom hemodynamically unstable, sustained mono- 
morphic ventricular tachycardia was inducible after 
approximately 10 days of treatment, sustained ven- 
tricular tachycardia was either no longer inducible or 
was inducible but slower and hemodynamically state 
2 months later. On the other hand, among 41% of 
patients who demonstrated an adequate response to 
amiodarone after short-term therapy, the response to 
amiodarone during electrophysiologic testing 13 f 4 
weeks later was no longer adequate, and hemody- 
namically unstable ventricular tachycardia was in- 
ducible. These findings demonstrate that the results 
of electrophysiologic testing after a high loading dose 
regimen may not accurately reflect the results that 
are found after several weeks of treatment with a 
maintenance dose of 400 mglday and indicate the 
importance of reevaluating patients after 3 months of 
therapy, even when the clinical course during the first 
2 or 3 months of therapy has been benign. In contrast 
to the variable effect of amiodarone on the inducibil- 
ity and hemodynamic stability of ventricular tachy- 
cardia after short-term and long-term treatment, its 
effect on measures of conduction and ventricular re- 
fractoriness were the same after 10 days and after 3 
months of therapy. 
Prognostic implications of the results of electrophys- 
iologic testing after short-term amiodarone therapy. Of 
note is that none of the patients in this study expe- 
rienced hemodynamically unstable ventricular ta- 
chycardia in the interval between the electrophysio- 
logic tests that were performed after short-term and 
after long-term therapy with amiodarone. Therefore 
although an acceptable response during electrophys- 
iologic testing after short-term therapy with amio- 
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darone does not guarantee that the response will still 
be acceptable 3 months later, the absence of induc- 
ible ventricular tachycardia that is hemodynamically 
unstable after short-term treatment suggest that the 
patient may be safely discharged from the hospital to 
await a repeat electrophysiologic test 3 months later. 
Electrophysiologic effects of amiodarone. Amio- 
darone prolongs the sinus cycle length and slows 
conduction throughout the heart.lm3> 7-g, 13-16 With a 
loading dose of amiodarone for 1 to 2 weeks and then 
a maintenance dose for 1 to 3 months, the prolonga- 
tion in sinus cycle length and the slowing of conduc- 
tion has been found to be maximal after 1 to 2 weeks 
of therapy.6-8, 14, 17, l8 The present study confirms this 
observation. 
In early experimental studies, when treatment 
with amiodarone was started at a low dosage, prolon- 
gation of the ventricular action potential was gradual 
in onset and maximal only after 6 weeks of 
treatment.l, 3, 5 In contrast, in studies in which a 
loading dose of amiodarone preceded treatment with 
a maintenance dose, significant electrophysiologic 
effects were present and often maximal after 1 to 2 
weeks of treatment.6a 8-g, 14, 18s lg In the present study, 
the mean total amiodarone loading dose was 
17.3 ? 6.8 gm, which is markedly higher than the 
loading doses that were used in previous studies. 
With this high loading dose of amiodarone, the elec- 
trophysiologic effects of amiodarone were maximal 
after approximately 10 days of treatment. Therefore 
although the effects of amiodarone on the results of 
programmed ventricular stimulation after 3 months 
of treatment cannot be accurately predicted after 10 
days of treatment, the effects on the sinus cycle 
length, on parameters of conduction, and on the ven- 
tricular effective refractory period are already max- 
imal after short-term treatment when a large loading 
dose is used. The discrepancy between the effects of 
amiodarone on measures of conduction and refracto- 
riness and the antiarrhythmic effect of amiodarone 
indicates that global measures of conduction and 
right ventricular refractoriness may not accurately 
reflect changes in the electrophysiologic properties of 
the reentry circuit. 
Effects of amiodarone on ventricular tachycardia and 
comparison with previous studies. The timing of the 
maximal antiarrhythmic effect of amiodarone has 
been the subject of several recent studies.6-8, lo, 11, lg 
These studies demonstrate that the response to ami- 
odarone during electrophysiologic testing may be 
better after long-term therapy than after short-term 
therapy. However, none of these studies included 
patients who had acceptable responses to amio- 
darone after short-term therapy. Previous studies 
have had a population size of 20 to 34 patients and 
have included patients who had inducible ventricu- 
lar fibrillation in the baseline electrophysiologic 
test.6l 7s lo Only the most recent studies included he- 
modynamic criteria for assessment of the antiar- 
rhythmic effect of amiodarone.6, l7 In contrast to 
previous studies, the present study included 71 
patients, each of whom had inducible, sustained, 
monomorphic ventricular tachycardia in the baseline 
state and each of whom underwent electrophysiologic 
testing after long-term treatment, even when a fa- 
vorable response had occurred after short-term treat- 
ment. 
Limitations. A limitation of this study is that it does 
not provide direct evidence that the results of elec- 
trophysiologic testing after 2 to 3 months of amio- 
darone therapy are clinically significant. When he- 
modynamically unstable ventricular tachycardia was 
inducible, patients either received combination ther- 
apy with a second antiarrhythmic drug or underwent 
implantation of an automatic defibrilator, in which 
case amiodarone therapy was discontinued or ta- 
pered in dosage. Therefore the natural history of pa- 
tients who demonstrated adequate responses to short- 
term therapy but inadequate responses to long-term 
therapy with amiodarone was not established in this 
study. 
Clinical implications. The results of this study have 
important clinical implications for the management 
of patients with life-threatening ventricular tachy- 
cardia who are treated with amiodarone. In patients 
in whom sustained and hemodynamically unstable 
ventricular tachycardia is inducible after 1 to 2 weeks 
of treatment with a loading dose of amiodarone, 
combination therapy with a class I ant&rhythmic 
drug may result in slowing of the ventricular tachy- 
cardia that is sufficient to result in hemodynamic 
stability during ventricular tachycardia. If this is the 
case, the patient may be safely discharged from the 
hospital with treatment that consists of the combi- 
nation of the class I drug and a maintenance dose of 
amiodarone. Repeat testing 2 to 3 months later, after 
discontinuation of treatment with the class I drug, 
may demonstrate that amiodarone by itself is suffi- 
cient to suppress the induction of ventricular tachy- 
cardia or to result in the induction of sustained ven- 
tricular tachycardia that is hemodynamically stable. 
These patients may then be safely treated on a long- 
term basis with amiodarone by itself, whereas the 
other patients may require continued treatment with 
a second drug or may be appropriate candidates for 
implantation of an automatic implantable cardio- 
verter-defibrillator. Some patients who demonstrate 
an adequate response to amiodarone during electro- 
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physiologic testing after 2 to 3 months of therapy 
might otherwise have been thought to be appropriate 
candidates for implantation of an autonomic cardio- 
verter-defibrillator, if the decision to implant the de- 
fibrillator were based on the results of electrophysi- 
ologic testing that was performed after short-term 
therapy. 
The results of this study also indicate the impor- 
tance of a follow-up electrophysiologic test after 2 to 
3 months of therapy with amiodarone in patients who 
demonstrate adequate short-term responses to ami- 
odarone. More than one third of patients who ini- 
tially respond adequately to amiodarone may be 
found to have inducible sustained ventricular tachy- 
cardia that is hemodynamically unstable 2 to 3 
months later and may therefore be appropriate can- 
didates for therapy with a second antiarrhythmic 
drug or for implantation of an autonomic implant- 
able cardioverter-defibrillator. 
It should be stressed that only patients in whom 
ventricular tachycardia was noninducible or induc- 
ible but hemodynamically stable after short-term 
therapy with amiodarone by itself or with a second 
drug were included in this study. Our results do not 
imply that the final decision to implant a defibrillator 
in a patient who has been treated with amiodarone 
for life-threatening ventricular tachycardia can al- 
ways be safely postponed for 2 to 3 months after an 
initial electrophysiologic test that demonstrates an 
inadequate response to amiodarone. Patients in 
whom sustained and hemodynamically unstable ven- 
tricular tachycardia remains inducible after short- 
term therapy with amiodarone may not tolerate or 
respond to combination therapy with a second anti- 
arrhythmic agent and may be appropriate immediate 
candidates for nonpharmacologic therapy, such as 
implantation of an autonomic defibrillator. 
The authors thank Marion Maguire for her excellent assistance 
in the preparation of the manuscript. 
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